http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113425723-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bad9b23c98772b92fc5921751f918e3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10 |
| filingDate | 2021-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c546f159deda94971311942635296e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17df2793569a702129e26645a6cb8aad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc0d8c775f4e2a5d07c1ff613d77399b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_213ee0306ac1b1ea0e77a021142659f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aef47973be2ac392f71140b59396e054 |
| publicationDate | 2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113425723-A |
| titleOfInvention | Application of Pim1 small molecule inhibitor in the preparation of products for the prevention and treatment of ankylosing spondylitis |
| abstract | The invention belongs to the field of medicine and biotechnology, and in particular relates to the application of Pim1 small molecule inhibitor in the preparation of products for preventing and treating ankylosing spondylitis. The invention uses Pim1 specific small molecule inhibitor AZD1208, and through in vivo and in vitro experiments proves that Pim1 is in Th17 The important role of Pim1 in differentiation confirmed that Pim1 can be used as a target to block Th17 differentiation and IL-17A secretion, and verified the safety, efficacy and feasibility of using AZD1208 to treat AS. Compared with IL-17A monoclonal antibody, pim1 treats AS by blocking Th17 differentiation, and is in the upstream of IL-17A monoclonal antibody in mechanism, so the present invention can provide a new target and a new way for the treatment of AS , providing a new option for AS patients, especially those with poor IL-17A monoclonal antibody treatment. |
| priorityDate | 2021-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 96.